Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (25)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

2021

  1. Mortality in Perinatally HIV-infected Adolescents after Transition to Adult Care in Spain

    Pediatric Infectious Disease Journal, Vol. 40, Núm. 4, pp. 347-350

  2. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. Addition of maraviroc versus placebo to standard antiretroviral therapy for initial treatment of advanced HIV infection: A randomized trial

    Annals of Internal Medicine, Vol. 172, Núm. 5, pp. 297-305

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792

2014

  1. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014)

    Enfermedades Infecciosas y Microbiologia Clinica Monografias, Vol. 32, Núm. 7, pp. 446e1-446e42

  2. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 7, pp. 447-458

  3. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597

  4. Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH

    Nefrologia, Vol. 34, Núm. 6, pp. 768-788

2011

  1. Clinical utility of maraviroc

    Clinical Drug Investigation, Vol. 31, Núm. 8, pp. 527-542

2010

  1. Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C

    AIDS Research and Human Retroviruses, Vol. 26, Núm. 4, pp. 419-424

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

  2. HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with virological failure to nucleoside drug combinations

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 251-258

  3. The Spanish HIV BioBank: A model of cooperative HIV research

    Retrovirology, Vol. 6

2006

  1. Recommendations of the Study Group for Metabolic Alterations/Secretariat for the National AIDS Plan (GEAM/SPNS) on the management of metabolic and morphologic alterations in patients with HIV infection

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. 2, pp. 96-117